“Is There a Role for Calcium Channel Blockers in the Contemporary Treatment Paradigm for Pulmonary Arterial Hypertension?” This is the title of an editorial by Lewis Rubin in Circulation, the journal of the American Heart Association, dated May 13, 2024.
Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute “vasoresponders”, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. But what about long-term outcomes?
Read more at this link on the Circulation website. The article can be accessed by paying.
